Shares of Tandem Diabetes Care soared over 10%, following the release of its first-quarter earnings report that showcased better-than-expected sales figures and reassuring forward guidance.

The medical device company, specializing in insulin delivery systems, reported Q1 sales of $234.42 million, significantly surpassing the analyst consensus estimate of $220.20 million. This represents a robust 22.3% increase compared to the same period last year. The company's worldwide sales growth was driven by a 22% increase in the United States and an impressive 35% growth outside the United States.

Despite the strong top-line performance, Tandem's adjusted earnings per share came in at a loss of $(0.67), slightly missing the expected loss of $(0.61) per share. However, investors appeared to focus on the revenue beat and the company's forward-looking statements. Tandem Diabetes Care provided fiscal year 2025 revenue guidance of $997 million to $1.007 billion, aligning closely with the consensus estimate of $999 million.

John Sheridan, president and chief executive officer, commented on the results: "The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States. We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability."

The company's strong performance in pump shipments, which reached 17,000 in the United States and 11,000 outside the United States, further underscored the growing demand for Tandem's diabetes management technologies. This solid growth, combined with the reaffirmed full-year guidance, has bolstered investor confidence in the company's growth trajectory and operational efficiency, driving the stock's significant rally.